Login to Your Account

'Path of Destruction'

As Dacogen Rejected, Firms Define Unmet Need for AML

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, March 12, 2012

Last week, Eisai Co. Ltd. and Astex Pharmaceuticals Inc. received a complete response letter for their request to expand the use of Dacogen (decitabine), which already is approved for myelodysplastic syndromes, into acute myeloid leukemia (AML) patients 65 years of age and older.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription